1. Home
  2. LBTYA vs RLAY Comparison

LBTYA vs RLAY Comparison

Compare LBTYA & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Global Ltd.

LBTYA

Liberty Global Ltd.

HOLD

Current Price

$9.60

Market Cap

4.0B

ML Signal

HOLD

Logo Relay Therapeutics Inc.

RLAY

Relay Therapeutics Inc.

HOLD

Current Price

$18.35

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBTYA
RLAY
Founded
2004
2015
Country
Bermuda
United States
Employees
6636
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
4.1B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
LBTYA
RLAY
Price
$9.60
$18.35
Analyst Decision
Hold
Strong Buy
Analyst Count
5
10
Target Price
$13.72
$19.50
AVG Volume (30 Days)
1.9M
3.5M
Earning Date
05-01-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.78
EPS
N/A
N/A
Revenue
N/A
$15,355,000.00
Revenue This Year
$15.41
N/A
Revenue Next Year
$3.03
$324.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
53.44
52 Week Low
$9.63
$3.03
52 Week High
$13.52
$20.79

Technical Indicators

Market Signals
Indicator
LBTYA
RLAY
Relative Strength Index (RSI) 25.06 50.31
Support Level N/A $6.67
Resistance Level $11.50 $20.79
Average True Range (ATR) 0.31 1.20
MACD -0.06 -0.28
Stochastic Oscillator 1.01 1.99

Price Performance

Historical Comparison
LBTYA
RLAY

About LBTYA Liberty Global Ltd.

Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.

About RLAY Relay Therapeutics Inc.

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.

Share on Social Networks: